| Literature DB >> 31057283 |
Mohammed Muneer1, Ayman El-Menyar2,3, Husham Abdelrahman4, Musab Ahmed Murad4, Sara M Al Harami1, Ahmed Mokhtar1, Mahwish Khawar1, Ahmed Awad5, Mohammad Asim2, Rifat Latifi6, Hassan Al-Thani4.
Abstract
INTRODUCTION: Morel-Lavallee lesion (MLL) is an infrequent or underreported serious consequence of closed degloving injuries. We aimed to describe the clinical presentation and management of pelvic MLL in obese patients.Entities:
Keywords: Degloving; Morel–Lavallee lesion; injury; obesity; pelvis; trauma
Year: 2019 PMID: 31057283 PMCID: PMC6496989 DOI: 10.4103/JETS.JETS_37_18
Source DB: PubMed Journal: J Emerg Trauma Shock ISSN: 0974-2700
STROBE statement – checklist of items that should be included in reports of observational studies
| Item number | Recommendation | Page | |
|---|---|---|---|
| Title and abstract | 1 | (a) Indicate the study design with a commonly used terms in the title or the abstract | 1 |
| (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 2-3 | ||
| Introduction | 3-4 | ||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 3 |
| Objectives | 3 | State-specific objectives, including any prespecified hypotheses | 6 |
| Methods | 4-6 | ||
| Study design | 4 | Present key elements of study design early in the paper | 4 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 4-6 |
| Participants | 6 | (a) Cohort study – Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-upCase–control study – Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controlsCross-sectional study – Give the eligibility criteria, and the sources and methods of selection of participants | 4-5 |
| (b) Cohort study – For matched studies, give matching criteria and number of exposed and unexposedCase–control study – For matched studies, give matching criteria and the number of controls per case | |||
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 4-6 |
| Data sources/measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 4-5 |
| Bias | 9 | Describe any efforts to address potential sources of bias | Page 3 and Table 6 |
| Study size | 10 | Explain how the study size was arrived at | 13 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 5 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 6 |
| (b) Describe any methods used to examine subgroups and interactions | |||
| (c) Explain how missing data were addressed | |||
| (d) Cohort study – If applicable, explain how loss to follow-up was addressedCase–control study – If applicable, explain how matching of cases and controls was addressedCross-sectional study – If applicable, describe analytical methods taking account of sampling strategy | - | ||
| (e) Describe any sensitivity analyses | - | ||
| Results | 6-8 | ||
| Participants | 13* | (a) Report numbers of individuals at each stage of study – e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed | |
| (b) Give reasons for nonparticipation at each stage | |||
| (c) Consider use of a flow diagram | |||
| Descriptive data | 14* | (a) Give characteristics of study participants (e.g., demographic, clinical, and social) and information on exposures and potential confounders | 6 |
| (b) Indicate number of participants with missing data for each variable of interest | |||
| (c) Cohort study – Summarize follow-up time (e.g., average and total amount) | |||
| Outcome data | 15* | Cohort study – Report numbers of outcome events or summary measures over time | 7-8 |
| Case–control study – Report numbers in each exposure category or summary measures of exposure | |||
| Cross-sectional study – Report numbers of outcome events or summary measures | |||
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 6-8 |
| (b) Report category boundaries when continuous variables were categorized | |||
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful period | |||
| Other analyses | 17 | Report other analyses done – e.g., analyses of subgroups and interactions and sensitivity analyses | |
| Discussion | 9-13 | ||
| Key results | 18 | Summarize key results with reference to study objectives | |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 13-14 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 9-13 |
| Generalizability | 21 | Discuss the generalizability (external validity) of the study results | |
| Other information | |||
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 15 |
Information on the STROBE Initiative is available at www.strobe-statement.org
Demographics, mechanism, and clinical characteristics of patients diagnosed with Morel–Lavallee lesion (n=183)
| Variable | Value (%) | Variable | Value (%) |
|---|---|---|---|
| Age (mean±SD) | 30.1±12.2 | Primary conservative management | 171 (93.4) |
| Males | 169 (92.3) | Observation | 134 (78.4) |
| Mechanism of injury | US-guided aspiration | 20 (11.7) | |
| Traffic-related accidents | 95 (51) | Pressure dressing | 1 (0.6) |
| Fall from height | 66 (36) | Not documented | 16 (9.7) |
| Others | 22 (13) | Primary surgical management for MLL | 12 (6.6) |
| BMI (mean±SD) kg/m2 | 37.4±10 | Incision and drainage | 2 (18.2) |
| BMI ≥30 | 138 (75.4) | Incision and drainage with VAC dressing | 1 (9.1) |
| Head AIS | 3.5±0.9 | Incision and drainage with debridement | 2 (18.2) |
| Pelvis AIS | 2.5±0.9 | Incision and drainage with VAC dressing and debridement | 5 (45.5) |
| ISS | 17.8±10.2 | Percutaneous management and drains | 1 (9.1) |
| GCS | 13±4 | Not documented | 1 (9.1) |
| Blood transfusion | 73 (40.0) | Failure of NOM* | 7 (3.8) |
| Blood units transfused | 6 (1-37) | Secondary surgical management for MLL | 7 (100) |
| Ventilatory days | 2 (1-16) | Duration of NOM | 24 (2-45) |
| ICU LOS | 4 (1-36) | Pelvic fracture | 80 (43.7) |
| Total LOS | 22 (1-192) | Surgical treatment for pelvic fracture# | 13 (16.2) |
| Complications | Disposition | ||
| Pneumonia | 8 (4.4) | Transfer to plastic surgery | 6 (3.3) |
| ARDS | 2 (1.1) | Rehabilitation | 9 (4.9) |
| Sepsis | 2 (1.1) | Transfer to other facility | 5 (2.7) |
| Discharged home | 140 (76.5) | ||
| Mortality | 23 (12.6) |
#12 cases underwent internal fixation and one case had external fixation, *Treated surgically. BMI: Body mass index, AIS: Abbreviated injury score, LOS: Length of stay, ARDS: Acute respiratory distress syndrome, US: Ultrasound, MLL: Morel–Lavallee lesion, VAC: Vacuum-assisted closure, NOM: Nonoperative management, ICU: Intensive Care Unit, SD: Standard deviation, GCS: Glasgow coma scale, ISS: Injury severity score
Figure 1Frequency of associated injuries in patients with Morel–Lavallee lesion
Figure 2Computed tomography scan images of Morel–Lavallee lesion with (a) left pelvic fracture and hematoma and (b) right femur fracture and hematoma
Figure 3Examples of management of Morel–Lavallee lesion: Incision and drainage with vacuum-assisted closure dressing and debridement
Management of cases with failure of nonoperative management (n=7)
| Initial operative management | Surgical intervention | |
|---|---|---|
| Case 1 (BMI=43) | Observation | Incision and drainage with debridement |
| Case 2 (BMI=44) | Observation | Incision and drainage with VAC dressing |
| Case 3 (BMI=43) | Observation | Incision and drainage with debridement |
| Case 4 (BMI=28) | US-guided aspiration | Incision and drainage with VAC dressing and debridement |
| Case 5 (BMI=52) | US-guided aspiration | Incision and drainage |
| Case 6 (BMI=29) | Observation | Incision and drainage with VAC dressing and debridement |
| Case 7 (BMI=44) | US-guided aspiration | Percutaneous management and drains |
VAC: Vacuum-assisted closure, BMI: Body mass index, US: Ultrasound
Management and outcome by injury severity
| ISS <15 (%) | ISS ≥15 (%) | ||
|---|---|---|---|
| 77 | 106 | ||
| Age | 29.3±11.7 | 30.7±12.6 | 0.42 |
| BMI | 37.2±10.9 | 37.7±9.2 | 0.73 |
| Pelvis AIS | 2.1±0.3 | 2.8±1.0 | 0.001 |
| Primary conservative management for MLL | 74 (96.1) | 97 (91.5) | 0.21 for all |
| Primary surgical treatment for MLL | 3 (3.9) | 9 (8.5) | |
| Secondary MLL surgical management | 4 (5.2) | 3 (2.8) | 0.41 |
| Pelvic fractures | 33 (42.9) | 47 (44.3) | 0.84 |
| Surgical treatment for pelvic fracture | 4 (5.2) | 9 (8.5) | 0.39 |
| Hospital length of stay | 22 (1-132) | 22 (1-92) | 0.88 |
| Mortality | 0 | 23 (21.7) | 0.001 |
ISS: Injury severity score, BMI: Body mass index, AIS: Abbreviated injury score, MLL: Morel–Lavallee lesion
Comparison between obese and nonobese Morel–Lavallee lesion patients
| Nonobese (BMI <30) (%) | Obese (BMI ≥30) (%) | ||
|---|---|---|---|
| 45 | 138 | ||
| Age (mean±SD) | 31.1±13 | 29.8±12 | 0.54 |
| Males | 42 (93.3) | 127 (92.0) | 0.77 |
| Method of initial MLL diagnosis | |||
| Clinical diagnosis only | 32 (71.1) | 121 (87.7) | 0.001 for all |
| Diagnosis missed on the initial clinical examination* | 11 (24.4) | 5 (3.6) | |
| Cases need confirmation by CT scan | 2 (4.4) | 12 (8.7) | |
| Pelvic fracture | 23 (51.1) | 57 (41.3) | 0.25 |
| Head injury | 8 (17.8) | 22 (15.9) | 0.77 |
| GCS (ED) | 12.7±4.5 | 13.2±4.0 | 0.51 |
| GCS (ED) <8 | 8 (18.2) | 18 (13.2) | 0.42 |
| Systolic blood pressure (ED) | 114±26 | 119±25 | 0.19 |
| Pelvis AIS | 2.4±0.8 | 2.5±0.9 | 0.58 |
| Injury severity score | 18±11 | 18±10 | 0.69 |
| Primary NOM | 43 (95.6) | 128 (92.8) | 0.51 |
| Duration of NOM in days | 23 (2-45) | 26 (5-40) | 0.50 |
| ICU stay | 3 (1-20) | 4 (1-36) | 0.66 |
| Total hospital stay in days | 19 (1-90) | 23 (1-192) | 0.78 |
| VAP | 1 (2.2) | 7 (5.1) | 0.39 |
| ARDS | 0 | 2 (1.4) | 0.42 |
| Sepsis | 0 | 2 (1.4) | 0.42 |
| Mortality | 5 (11.1) | 18 (13) | 0.73 |
*Initially missed on clinical evaluation later diagnosed by CT scan. ED: Emergency department, NOM: Nonoperative management, MLL: Morel–Lavallee lesion, SD: Standard deviation, CT: Computed tomography, GCS: Glasgow coma scale, AIS: Abbreviated injury score, ICU: Intensive Care Unit, VAP: Ventilator-associated pneumonia, ARDS: Acute respiratory distress syndrome, BMI: Body mass index
Severity and outcome in obese Morel–Lavallee lesion patients (n=138)
| Grade I (BMI 30-34.99) (%) | Grade II (BMI 35-39.99) (%) | Grade III (BMI ≥40) (%) | ||
|---|---|---|---|---|
| 28 (20.3) | 32 (23.2) | 78 (56.5) | ||
| Age (mean±SD) | 28.7±8.5 | 32.4±11.9 | 29.1±13.1 | 0.16 |
| Males | 26 (93.0) | 27 (84.0) | 74 (95.0) | 0.18 |
| Injury severity score | 18±12 | 18±10 | 17±9 | 0.44 |
| Pelvis AIS | 2.7±0.9 | 2.5±0.9 | 2.4±0.8 | 0.22 |
| Pelvic fractures | 10 (36.0) | 14 (44.0) | 33 (42.0) | 0.79 |
| Conservative management for MLL | 26 (92.9) | 30 (93.8) | 67 (85.9) | 0.39 for all |
| Surgical treatment for MLL | 2 (7.1) | 2 (6.3) | 6 (7.7) | |
| Secondary MLL surgical management | 0 | 0 | 5 (6.4) | |
| Surgical treatment for pelvic fracture | 3 (10.7) | 1 (3.1) | 6 (7.7) | 0.51 |
| Blood transfusion | 11 (39.3) | 12 (37.5) | 30 (38.5) | 0.99 |
| Blood unit transfused | 10±8 | 3±1 | 12±10 | 0.002 |
| Pneumonia | 2 (7.1) | 1 (3.1) | 4 (5.1) | 0.78 |
| ARDS | 1 (3.6) | 0 | 1 (1.3) | 0.50 |
| Sepsis | 0 | 0 | 2 (2.6) | 0.46 |
| Hospital length of stay | 22 (1-81) | 23 (1-192) | 23 (1-132) | 0.62 |
| ICU length of stay | 3 (1-24) | 3.5 (1-36) | 4 (1-22) | 0.61 |
| Mortality | 5 (17.9) | 3 (9.4) | 10 (12.8) | 0.62 |
AIS: Abbreviated injury score, ICU: Intensive Care Unit, SD: Standard deviation, MLL: Morel–Lavallee lesion, ARDS: Acute respiratory distress syndrome, BMI: Body mass index
Predictors of mortality in Morel–Lavallee lesion cases
| Variables | OR | 95% CI | |
|---|---|---|---|
| Age | 1.007 | 0.929-1.091 | 0.86 |
| BMI | 1.106 | 0.968-1.263 | 0.140 |
| Head injury | 3.153 | 0.274-36.353 | 0.357 |
| Pelvic fracture | 0.949 | 0.069-13.116 | 0.969 |
| Injury severity score | 1.254 | 1.047-1.500 | 0.014 |
| GCS (ED) | 0.716 | 0.558-0.918 | 0.008 |
ED: Emergency department, CI: Confidence interval, BMI: Body mass index, GCS: Glasgow coma scale, OR: Odds ratio